AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02498028 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical disc Prostheses
Description: The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
Study NCT04770675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: All subjects who are scheduled for a bronchoscopy may be eligible.
Study NCT00086502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
Study NCT00086502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Pioglitazone
Description: Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
Study NCT05456230 — intervention group
Intervention type: DRUG
Intervention: Midazolam
Description: Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
Study NCT04584762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Variable Pressure Insufflation
Description: Acute migraine treatment
Study NCT04584762 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Automated Variable Pressure Insufflation
Description: Acute migraine treatment
Study NCT00086502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Pioglitazone
Description: Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
Study NCT00086502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8
Study NCT00086502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8
Study NCT04810936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplements
Description: Oral nutritional supplements is usually administrated to improve nutritional status in cancer patients.
Study NCT03490149 — intervention group
Intervention type: DEVICE
Intervention: Electroconvulsive Therapy
Description: Series of electroconvulsive therapy for major depressive disorder
Study NCT03490149 — intervention group
Intervention type: DRUG
Intervention: Medication - Treatment as usual
Description: Medication only sample - Treatment as usual
Study NCT01304329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Medium dose oral administration
Study NCT01304329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Medium dose oral administration
Study NCT02183129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Study NCT02183129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Study NCT01592617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-488410
Description: In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
Study NCT04101617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health education including printed educational material
Description: Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
Study NCT04053595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic parameters of fluid responsiveness protocol
Description: Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume >10% after fluid administration.
Study NCT04053595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Estimated oxygen extraction protocol
Description: Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
Study NCT02809755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Lidocaine
Study NCT02809755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00754325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, once daily (QD), upto 2 years
Study NCT00754325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
Study NCT03606889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tranversus Abdominis plane block
Description: 0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
Study NCT03606889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.2 ml/kg bupivicaine
Study NCT03996525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~1. Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~2. Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision.
Study NCT03996525 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Treatment
Description: Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~1. Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~2. Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision.
Study NCT01813149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine and clonidine
Description: Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
Study NCT01813149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: punch biopsy
Study NCT01885962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSHIFTup
Description: Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
Study NCT02706561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT02706561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: three in-person sessions
Study NCT00396812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid.
Study NCT00242632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namenda
Description: Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
Study NCT02753920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: voiding trial
Description: 1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
Study NCT02753920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
Study NCT03776916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simethicone administration 20-30 min before the procedure
Description: Patients intake simethicone 20-30 min before the procedure
Study NCT03776916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simethicone administration 31-60 min before the procedure
Description: Patients intake simethicone administration 31-60 min before the procedure.
Study NCT03776916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simethicone administration > 60 min before the procedure
Description: Patients intake simethicone administration > 60 min before the procedure.
Study NCT02706561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: monthly phone calls
Study NCT02706561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)
Study NCT02706561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Monitoring and Education (EME)
Study NCT04266470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lara Scan
Description: Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan.
Study NCT04266470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Scan - Pre-treatment and Post-treatment
Description: The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
Study NCT01842581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be administered per the dose and schedule specified in the arms.
Study NCT01842581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Laculose will be administered per the schedule specified in the respective arm.
Study NCT03738319 — intervention group
Intervention type: GENETIC
Intervention: Sequencing of miRNA/lncRNA
Description: Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
Study NCT03368014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lyrics-writing and singing show
Description: Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony.
Study NCT01020708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalamine
Description: 4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
Study NCT01020708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTH12-1:4
Description: ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
Study NCT01020708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTH12-2:4
Description: ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
Study NCT01656369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I: delorme operation only.
Description: A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
Study NCT04627168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive, surface electrical stimulation device, DS5 Digitimer
Description: Transcutaneous abdominal electrical stimulation will be delivered through the commercially available equipment, a DS5 Digitimer.
Study NCT02350400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEBIRI
Description: DEBIRI TACE
Study NCT01656369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delorme operation with post anal repair
Description: In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
Study NCT02159677 — intervention group
Intervention type: DEVICE
Intervention: EIM Measurements
Study NCT02358655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective review of OAC prescription
Study NCT02358655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prescription of OAC in ED
Study NCT02358655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community AF clinic
Study NCT01308151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other
Description: No interventions other than the culturally adapted manualised cognitive behavioral therapy
Study NCT00620672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: omega 3 fatty acids
Description: The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
Study NCT00620672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: vegetable oil
Description: The supplement is a dietary supplement of vegetable oil as a placebo
Study NCT03316755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Exposure to pamphlet
Study NCT02976194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
Study NCT04754568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality instructional design
Description: 60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
Study NCT03783611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0.
Description: eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
Study NCT04262713 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Radiographs
Description: Radiographs of the implanted hip with Meije duo size1 or 2 are performed in eligible patients ( Weigh>60, Long neck stem, Varus; DEVANE score ≥ 4)
Study NCT01735708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIVPASS
Study NCT01735708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Study NCT02190305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplo HBc/HIV/HCV and Reveal HBsAg
Description: All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
Study NCT02784015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02784015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02784015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02784015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02784015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT02784015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02784015 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02784015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Study NCT02784015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT00650520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
Description: 4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study NCT00650520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
Description: 4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study NCT01971216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Study NCT03288194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment
Study NCT03288194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time Management
Study NCT04399954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketoflo
Description: Ketoflo is a ready to use liquid feed for the dietary management of epilepsy and other conditions that may require a ketogenic diet. It has a 4:1 ratio of fat to carbohydrate and protein and can be administered enterally via a tube feeding or oral consumption.
Study NCT00542737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Educational Program
Description: Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
Study NCT00964847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga exercise program
Description: Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
Study NCT00964847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga exercise program
Description: Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.